278 related articles for article (PubMed ID: 23146507)
21. Orthotopic liver transplantation for hepatocellular carcinoma: a thirteen-year single-center experience.
Castroagudín JF; Molina E; Bustamante M; Tomé S; Otero E; Martínez J; Segade FR; Conde R; Varo E
Transplant Proc; 2008 Nov; 40(9):2975-7. PubMed ID: 19010164
[TBL] [Abstract][Full Text] [Related]
22. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
Jiang L; Liao A; Yan L; Li B; Zhu W; Wen T
Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
[TBL] [Abstract][Full Text] [Related]
23. Hepatocellular carcinoma recurrence among liver transplant recipients within the Milan criteria.
Felga G; Evangelista AS; Salvalaggio PR; Curvelo LA; Della Guardia B; Almeida MD; Afonso RC; Ferraz-Neto BH
Transplant Proc; 2012 Oct; 44(8):2459-61. PubMed ID: 23026620
[TBL] [Abstract][Full Text] [Related]
24. The impact of Milan criteria on liver transplantation for hepatocellular carcinoma: first 15 years' experience of the Hungarian Liver Transplant Program.
Nemes B; Gelley F; Piros L; Zádori G; Görög D; Fehérvári I; Kóbori L; Sárváry E; Nagy P; Kiss A; Doros A
Transplant Proc; 2011 May; 43(4):1272-4. PubMed ID: 21620108
[TBL] [Abstract][Full Text] [Related]
25. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
26. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
[TBL] [Abstract][Full Text] [Related]
27. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
[TBL] [Abstract][Full Text] [Related]
28. Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepatocellular carcinoma.
Piardi T; Gheza F; Ellero B; Woehl-Jaegle ML; Ntourakis D; Cantu M; Marzano E; Audet M; Wolf P; Pessaux P
Ann Surg Oncol; 2012 Jun; 19(6):2020-6. PubMed ID: 22179632
[TBL] [Abstract][Full Text] [Related]
29. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time.
Decaens T; Roudot-Thoraval F; Hadni-Bresson S; Meyer C; Gugenheim J; Durand F; Bernard PH; Boillot O; Sulpice L; Calmus Y; Hardwigsen J; Ducerf C; Pageaux GP; Dharancy S; Chazouilleres O; Cherqui D; Duvoux C
Liver Transpl; 2006 Dec; 12(12):1761-9. PubMed ID: 16964590
[TBL] [Abstract][Full Text] [Related]
30. Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed?
Castroagudín JF; Molina-Pérez E; Ferreiro-Iglesias R; Abdulkader I; Otero-Antón E; Tomé S; Varo-Pérez E
Transplant Proc; 2012; 44(6):1565-7. PubMed ID: 22841215
[TBL] [Abstract][Full Text] [Related]
31. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
[TBL] [Abstract][Full Text] [Related]
32. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma.
Decaens T; Roudot-Thoraval F; Badran H; Wolf P; Durand F; Adam R; Boillot O; Vanlemmens C; Gugenheim J; Dharancy S; Bernard PH; Boudjema K; Calmus Y; Hardwigsen J; Ducerf C; Pageaux GP; Hilleret MN; Chazouillères O; Cherqui D; Mallat A; Duvoux C
Liver Int; 2011 Jul; 31(6):792-801. PubMed ID: 21645209
[TBL] [Abstract][Full Text] [Related]
33. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation.
Tamura S; Kato T; Berho M; Misiakos EP; O'Brien C; Reddy KR; Nery JR; Burke GW; Schiff ER; Miller J; Tzakis AG
Arch Surg; 2001 Jan; 136(1):25-30; discussion 31. PubMed ID: 11146770
[TBL] [Abstract][Full Text] [Related]
34. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
Na GH; Kim EY; Hong TH; You YK; Kim DG
HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
[TBL] [Abstract][Full Text] [Related]
35. Patients with unresectable hepatocellular carcinoma beyond Milan criteria: should we perform transarterial chemoembolization or liver transplantation?
Kim JM; Kwon CH; Joh JW; Kim SJ; Shin M; Kim EY; Moon JI; Jung GO; Choi GS; Lee SK
Transplant Proc; 2010 Apr; 42(3):821-4. PubMed ID: 20430181
[TBL] [Abstract][Full Text] [Related]
36. Living donor liver transplantation for hepatocellular carcinoma: Increased recurrence but improved survival.
Vakili K; Pomposelli JJ; Cheah YL; Akoad M; Lewis WD; Khettry U; Gordon F; Khwaja K; Jenkins R; Pomfret EA
Liver Transpl; 2009 Dec; 15(12):1861-6. PubMed ID: 19938113
[TBL] [Abstract][Full Text] [Related]
37. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation.
Ito T; Takada Y; Ueda M; Haga H; Maetani Y; Oike F; Ogawa K; Sakamoto S; Ogura Y; Egawa H; Tanaka K; Uemoto S
Liver Transpl; 2007 Dec; 13(12):1637-44. PubMed ID: 18044766
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio.
Harimoto N; Shirabe K; Nakagawara H; Toshima T; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Ikeda T; Maehara Y
Transplantation; 2013 Dec; 96(11):1008-12. PubMed ID: 24113512
[TBL] [Abstract][Full Text] [Related]
39. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma.
Soejima Y; Taketomi A; Yoshizumi T; Uchiyama H; Aishima S; Terashi T; Shimada M; Maehara Y
Transplantation; 2007 Apr; 83(7):893-9. PubMed ID: 17460559
[TBL] [Abstract][Full Text] [Related]
40. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
